menu
    • menu

    Company profile for Orum Therapeutics

    Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.

    Virtual Booth

    Contact Supplier

    Global Pharma Healthcare: Setting the global benchmark in quality, innovation, and care

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Orum Therapeutics is combining the precision of antibodies with the power of targeted protein degraders to bring new medicines to patients with unmet medical needs. Orum (오름) means ‘ascent’ in Korean, climbing or moving upwards. Our vision is a world where no patient suffers from diseases caused by undruggable targets. Orum’s antibody platform can intracellularly deliver an active antibody therapeutic or payload, i...
    Orum Therapeutics is combining the precision of antibodies with the power of targeted protein degraders to bring new medicines to patients with unmet medical needs. Orum (오름) means ‘ascent’ in Korean, climbing or moving upwards. Our vision is a world where no patient suffers from diseases caused by undruggable targets. Orum’s antibody platform can intracellularly deliver an active antibody therapeutic or payload, is easily adaptable to target different cell types and intracellular proteins, and does not require chemical modification.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Orum TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    20 Acorn Park Drive Ste 501 Cambridge, MA 02140
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.orumrx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/orum-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Orum Names Chad May as Chief Scientific Officer
    Orum Names Chad May as Chief Scientific Officer

    05 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-05/orum-therapeutics-appoints-chad-may-as-chief-scientific-officer-to-drive-degrader-antibody-conjugate

    PHARMIWEB
    05 Jan 2026
    Share Share
    Orum Pharma Names Chad May as Chief Scientific Officer
    Orum Pharma Names Chad May as Chief Scientific Officer

    04 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260105027779/en/Orum-Therapeutics-Appoints-Chad-May-as-Chief-Scientific-Officer-to-Drive-Degrader-Antibody-Conjugate-Innovation-and-Programs

    BUSINESSWIRE
    04 Jan 2026
    Share Share
    Orum Therapeutics Secures $100M for Degrader Programs
    Orum Therapeutics Secures $100M for Degrader Programs

    18 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-18/orum-therapeutics-secures-approximately-us-100-million-to-accelerate-development-of-leading-degrader

    PHARMIWEB
    18 Dec 2025
    Share Share
    Orum Therapeutics Unveils Potent ORM-1153 Data at ASH 2025
    Orum Therapeutics Unveils Potent ORM-1153 Data at ASH 2025

    08 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-08/orum-therapeutics-presents-preclinical-data-at-ash-2025-demonstrating-potent-and-selective-antitumor

    PHARMIWEB
    08 Dec 2025
    Share Share
    Orum Therapeutics Presents ORM-1153 Preclinical Data at ASH 2025
    Orum Therapeutics Presents ORM-1153 Preclinical Data at ASH 2025

    03 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251103001400/en/Orum-Therapeutics-Announces-Presentation-of-Preclinical-Data-for-ORM-1153-at-the-2025-American-Society-of-Hematology-ASH-Annual-Meeting

    BUSINESSWIRE
    03 Nov 2025
    Share Share
    Orum Names Dorin Toader to Lead Degrader–Antibody Platforms
    Orum Names Dorin Toader to Lead Degrader–Antibody Platforms

    15 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-15/orum-therapeutics-appoints-dr-dorin-toader-as-head-of-platform-technology-to-advance-orum-s-degrade

    PHARMIWEB
    15 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search